Evidence map›Paper›PMID 23594796›Full record

ArticleMolecular cancer research : MCR2013

Interactions between SAP155 and FUSE-binding protein-interacting repressor bridges c-Myc and P27Kip1 expression.

Kazuyuki Matsushita, Mai Tamura, Nobuko Tanaka, Takeshi Tomonaga, Hisahiro Matsubara, Hideaki Shimada, David Levens, Liusheng He, Juhong Liu, Minoru Yoshida and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Oncotarget · 2017
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Kazuyuki MatsushitaDepartment of Molecular Diagnosis (F8), Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. kmatsu@faculty.chiba-u.jp
Mai Tamura
Nobuko Tanaka
Takeshi Tomonaga
Hisahiro Matsubara
Hideaki Shimada
David Levens
Liusheng He
Juhong Liu
Minoru Yoshida
Fumio Nomura
National Cancer Institute · USRIKEN · JPNational Institute of Biomedical Innovation, Health and Nutrition · JPChiba University · JP

Funding

c-Myc FunctionZIABC011465 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LEVENS, DAVID L. · 2012 to 2025
$8.6M
Mechanisms of transcription factor integration at the c-myc promoterZ01SC009144 · SC · DIVISION OF CLINICAL SCIENCES - NCI · PI LEVENS, DAVID L. · 1996 to 2008
$3.1M
Intramural NIH HHS Z01 SC009144
6 · The paper itself

Abstract

Oncogenic c-Myc plays a critical role in cell proliferation, apoptosis, and tumorigenesis, but the precise mechanisms that drive this activity remain largely unknown. P27Kip1 (CDKN1B) arrests cells in G1, and SAP155 (SF3B1), a subunit of the essential splicing factor 3b (SF3b) subcomplex of the spliceosome, is required for proper P27 pre-mRNA splicing. FUSE-binding protein-interacting repressor (FIR), a splicing variant of PUF60 lacking exon5, is a c-Myc transcriptional target that suppresses the DNA helicase p89 (ERCC3) and is alternatively spliced in colorectal cancer lacking the transcriptional repression domain within exon 2 (FIRΔexon2). FIR and FIRΔexon2 form a homo- or hetero-dimer that complexes with SAP155. Our study indicates that the FIR/FIRΔexon2/SAP155 interaction bridges c-Myc and P27 expression. Knockdown of FIR/FIRΔexon2 or SAP155 reduced p27 expression, inhibited its pre-mRNA splicing, and reduced CDK2/Cyclin E expression. Moreover, spliceostatin A, a natural SF3b inhibitor, markedly inhibited P27 expression by disrupting its pre-mRNA splicing and reduced CDK2/Cyclin E expression. The expression of P89, another FIR target, was increased in excised human colorectal cancer tissues. Knockdown of FIR reduced P89; however, the effects on P27 and P89 expression are not simply or directly related to altered FIR expression levels, indicating that the mechanical or physical interaction of the SAP155/FIR/FIRΔexon2 complex is potentially essential for sustained expression of both P89 and P27. Together, the interaction between SAP155 and FIR/FIRΔexon2 not only integrates cell-cycle progression and c-Myc transcription by modifying P27 and P89 expression but also suggests that the interaction is a potential target for cancer screening and treatment.

Indexed as

Alternative SplicingCell Line, TumorCell ProliferationColonic NeoplasmsCyclin-Dependent Kinase Inhibitor p27Cyclin EDNA-Binding ProteinsDNA HelicasesG1 Phase Cell Cycle CheckpointsGene Knockdown TechniquesHumansModels, BiologicalPhosphoproteinsProtein BindingProto-Oncogene Proteins c-mycPyransCyclin-Dependent Kinase Inhibitor p27Cyclin EDNA-Binding ProteinsDNA HelicasesPhosphoproteinspoly-U binding splicing factor 60KDaProto-Oncogene Proteins c-mycPyransRepressor ProteinsRibonucleoprotein, U2 Small NuclearRNA-Binding ProteinsRNA PrecursorsRNA, Small InterferingRNA Splicing FactorsSF3B1 protein, humanSpiro Compoundsspliceostatin ATranscription Factor TFIIHXPBC-ERCC-3 protein

Identifiers

PMID23594796
PMCPMC7589523
OpenAlexW2152734167

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.